SUXIBUZONE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H26N2O6
Molecular Weight	438.473
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCCCC1(COC(=O)CCC(O)=O)C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3

InChI

InChIKey=ONWXNHPOAGOMTG-UHFFFAOYSA-N

InChI=1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)

HIDE SMILES / InChI

Molecular Formula	C24H26N2O6
Molecular Weight	438.473
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.grovet.com/danilon.html
Curator's Comment: description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/23959620

In 2012, two newly developed active pharmaceutical ingredients for horses and food producing animals were released on the German market for veterinary drug products. Those are the parenterally applicable first generation cephalosporin Cefalonium (Cepravin) and the nonsteroidal anti-inflammatory drug Suxibuzone (Danilon). Suxibuzone is a d drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation. It is a prodrug of the phenylbutazone, which inactivates prostaglandin H synthase and prostacyclin synthase

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin G/H synthase 2 51 Target ID: O19183 Gene ID: 791253.0 Gene Symbol: PTGS2 Target Organism: Equus caballus (Horse) Sources: http://www.ncbi.nlm.nih.gov/pubmed/20037965	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Osteoarthritis 157 Sources: http://www.grovet.com/danilon.html	Palliative	Approved 8583	Danilon Approved Use Danilon Equidos is a non-steroidal anti-inflammatory drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.
Laminitis 1 Sources: http://www.grovet.com/danilon.html	Palliative	Approved 8583	Danilon Approved Use Danilon Equidos is a non-steroidal anti-inflammatory drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.
Bursitis 6 Sources: http://www.grovet.com/danilon.html	Palliative	Approved 8583	Danilon Approved Use Danilon Equidos is a non-steroidal anti-inflammatory drug for treatment of pain and inflammation associated with musculoskeletal conditions in the horse eg. osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation.

Doses

Dose	Population	Adverse events
426 mg single, oral Studied dose Dose: 426 mg Route: oral Route: single Dose: 426 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7097505/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/7097505/	Sources: https://pubmed.ncbi.nlm.nih.gov/7097505/

PubMed

Title	Date	PubMed
Antemortem diagnosis of a distal axonopathy causing severe stringhalt in a horse.	2009-12-17	20002548
Rapid confirmatory analysis of non-steroidal anti-inflammatory drugs in bovine milk by rapid resolution liquid chromatography tandem mass spectrometry.	2009-11-13	19501363
Multicentre, controlled, randomised and blinded field study comparing efficacy of suxibuzone and phenylbutazone in lame horses.	2009-09	19927590
Effects of top-dress formulations of suxibuzone and phenylbutazone on development of gastric ulcers in horses.	2009	20037965
Evaluation of the palatability of three nonsteroidal antiinflammatory top-dress formulations in horses.	2008	18597250
Lower gastric ulcerogenic effect of suxibuzone compared to phenylbutazone when administered orally to horses.	2004-04	14672858
Screening procedure for detection of non-steroidal anti-inflammatory drugs and their metabolites in urine as part of a systematic toxicological analysis procedure for acidic drugs and poisons by gas chromatography-mass spectrometry after extractive methylation.	2001-06-02	11386636
Diagnosis of antibody-mediated drug allergy. Pyrazolinone and pyrazolidinedione cross-reactivity relationships.	1987-11	3425858
Promotion of hepatocarcinogenesis by suxibuzone in rats initiated with 3'-methyl-4-dimethylaminoazobenzene.	1987-07	3107799

Patents

Sample Use Guides

In Vivo Use Guide

for horses: For a 480 kg horse: administer 2 sachets twice daily for 2 days (equivalent to 12.5 mg suxibuzone/kg/day). Follow by administering 1 sachet twice daily for 3 days (equivalent to 6.25 mg suxibuzone/kg/day). Ponies: For a 240 kg pony: administer 1 sachet daily for 2 days (equivalent to 6.25 mg of suxibuzone/kg/day).

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:17:16 GMT 2025` Edited by `admin` on `Mon Mar 31 18:17:16 GMT 2025`
Record UNII	86TDZ5WP2B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SUXIBUZONE [JAN]

Preferred Name

English

SUXIBUZONE

Official Name

English

SUXIBUZONE [MART.]

Common Name

English

NSC-757866

Code

English

SUXIBUZONE [EP MONOGRAPH]

Common Name

English

Suxibuzone [WHO-DD]

Common Name

English

SUXIBUZONE [EP IMPURITY]

Common Name

English

suxibuzone [INN]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QM02AA22